Evolus Inc. (EOLS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Evolus Inc. (EOLS:NASDAQ), powered by AI.

Current Price
$6.63
P/E Ratio
-8.3
Market Cap
427M
Sector
Healthcare
What is the Evolus Inc. stock price forecast?

Evolus Inc. is currently trading at $6.63. View real-time AI analysis on Alpha Lenz.

What is Evolus Inc. insider trading activity?

View the latest insider trading data for Evolus Inc. on Alpha Lenz.

What is Evolus Inc.'s P/E ratio?

Evolus Inc.'s P/E ratio is -8.3.

Evolus Inc.

NASDAQ · EOLS
$6.63-0.12(-1.78%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Evolus Inc.'s future dividend policy...
Alpha Chat Insight

Evolus Inc. trades at a P/E of -8.3 (undervalued) with strong ROE of 587.4%. 3Y revenue CAGR of 26.0% highlights clear growth momentum.

Ask for details

Company Overview

Evolus Inc. is a medical aesthetics company that is primarily known for its focus on aesthetic dermatology. The company's flagship product is Jeuveau, a botulinum toxin type A formulation intended for aesthetic use, specifically to reduce the appearance of frown lines in adults. Evolus Inc. serves the healthcare and beauty industry by providing solutions for individuals seeking non-surgical aesthetic procedures. Headquartered in Newport Beach, California, the company emphasizes innovation in its approach to cosmetic treatments, aiming to offer cost-effective alternatives to existing products. Evolus's operations impact the broader aesthetic medicine sector by enabling aesthetic professionals and clinics to expand their treatment offerings. As a publicly traded entity, the company plays a crucial role in the competitive landscape of aesthetic pharmaceutical products, contributing to the growing demand for cosmetic enhancements and minimally invasive procedures. Evolus Inc.'s performance and strategic developments are closely watched by investors and industry stakeholders due to its unique positioning within the medical aesthetics market.

CEOMr. David Moatazedi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees394

Company Statistics

FY 2025

Profile

$427.43MMarket Cap
$297.18MRevenue
0.00Shares Out
394Employees

Margins

66.33%Gross
-7.09%EBITDA
-12.65%Operating
-17.15%Pre-Tax
-17.38%Net

Valuation

-8.28P/E
-18.50P/B
1.44EV/Sales
-25.07EV/EBITDA
-8.43P/FCF

Growth (CAGR)

25.98%Rev 3Yr
39.36%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-22.53%ROA
587.36%ROE
-13.64%ROIC

Financial Health

$53.83MCash & Cash Equivalents
$195.15MNet Debt
-1077.53%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Evolus Inc. (ticker: EOLS) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 394 employees. Market cap is $427M.

The current price is $6.63 with a P/E ratio of -8.28x and P/B of -18.5x.

ROE is 587.36% and operating margin is -12.65%. Annual revenue is $297M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Evolus Inc. (EOLS) Stock Forecast 2026 $6.63 — Price, Financials & Analyst Targets | Alpha Lenz